

Cancer Supportive Care Drugs Market to Reach \$24.40 Bn, Globally, by 2030 at 2.2% CAGR: Allied Market Research

The escalating prevalence of cancer necessitates chemotherapy, intensifying its associated adverse effects & propelling the cancer supportive care drugs market.

PORTLAND, OR, UNITED STATES, July 10, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "[Cancer Supportive Care Drugs Market](#)" is generated \$19.63 billion in 2020, and is expected to reach \$24.40 billion by 2030, witnessing a CAGR of 2.2% from 2021 to 2030. The escalating prevalence of cancer necessitates chemotherapy, intensifying its associated adverse effects and propelling the cancer supportive care drugs market. For instance, the American Cancer Society in 2023, stated that 10% of people were living with metastatic colorectal cancer in the U.S., in 2022.

□ Download Summary -

<https://www.alliedmarketresearch.com/request-sample/7498>



Cancer Supportive Care Drugs Market Research, 2032

Market Dynamics: Driving Forces, Challenges, and Future Prospects

The global cancer supportive care drugs market is on a steady rise, driven by a surge in cancer cases worldwide, growing adoption of biosimilars, and increased government investment in healthcare infrastructure. The need to manage the adverse effects of cancer therapies has also fueled demand for supportive care drugs. However, this growth is somewhat tempered by the rising preference for targeted therapies, which reduce the need for ancillary treatments, and the complex, time-consuming regulatory approval process for biosimilars. On the bright side, expanding R&D pipelines, a growing focus on drug development, and opportunities within untapped emerging markets offer promising growth avenues for the industry in the coming years.

COVID-19 Disruption and Its Aftermath

The COVID-19 pandemic posed significant challenges to the cancer supportive care drugs market. Global manufacturing operations and pharmaceutical supply chains were disrupted, delaying drug production and distribution. Ongoing clinical trials and R&D efforts experienced setbacks, with approvals for new supportive therapies postponed. Additionally, many cancer patients deferred chemotherapy sessions during the pandemic, leading to a temporary drop in demand for supportive care drugs. As healthcare systems recover, these delays are gradually being addressed, and demand is projected to rebound.

□ Get detailed COVID-19 impact analysis on the Cancer Supportive Care Drugs Market - <https://www.alliedmarketresearch.com/request-for-customization/7498?reqfor=covid>

Segment Analysis: G-CSFs and Retail Pharmacies Leading the Way

Among the drug types, the G-CSFs (Granulocyte Colony-Stimulating Factors) segment emerged as the market leader in 2020, accounting for more than 40% of the market share. This dominance is expected to continue through 2030, driven by the high prevalence of chemotherapy-induced neutropenia (CIN) and the strong demand for G-CSFs to manage this condition. Meanwhile, the antiemetics segment is projected to witness the fastest growth, with a CAGR of 2.4% through 2030, owing to its effectiveness in improving patient quality of life during cancer treatment.

In terms of distribution, drug stores and retail pharmacies held nearly half of the market share in 2020 and are expected to maintain their lead due to their accessibility, availability of a wide range of branded and generic drugs, and attractive discounts. However, hospital pharmacies are set to register the highest CAGR of 2.3% during the forecast period, supported by the convenience and reliability of in-hospital medication access and consultation with healthcare professionals.

Looking Ahead

As cancer treatment protocols evolve and patient-centric care gains importance, the need for effective supportive therapies continues to grow. With robust R&D pipelines and increasing awareness, the cancer supportive care drugs market is well-positioned for expansion in the years ahead.

□ Want Full Synopsis? Proceed to Buy - <https://www.alliedmarketresearch.com/purchase-enquiry/7498>

North America to maintain its dominance by 2030

Based on region, North America contributed to the highest market share in 2020, accounting for around two-fifths of the global cancer supportive care drugs market, and is expected to maintain

its dominance by 2030. This is due to increase in prevalence of cancer, strong presence of key players, huge availability of drugs, early diagnosis, and favorable reimbursement policies in this region. However, Asia-Pacific is estimated to witness the fastest CAGR of 2.3% from 2021 to 2030, owing to surge in healthcare expenditure and adoption of strategies such as merger, acquisition, and expansion by major market players in the Asia-Pacific region.

Leading Market Players

- Amgen Inc.
- Baxter International Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc (GSK) (Tesar)
- Helsinn Healthcare
- Heron Therapeutics
- Johnson & Johnson (Janssen Global Services, LLC,)
- Merck KGAA
- Novartis International AG (Sandoz)
- Teva Pharmaceuticals

Frequently Asked Questions?

Q1. What is cancer supportive care drugs?

Q2. What are the key trends in the cancer supportive care drugs market report?

Q3. Which is the most influencing segment growing in the cancer supportive care drugs market report?

Q4. Which are the top companies to hold the market share in Cancer Supportive Care Drugs?

Q5. Which is base year calculated in the cancer supportive care drugs market report?

☐☐☐ Exclusive Related Reports with “Market Insights” ☐☐☐

Cell culture market - <https://www.alliedmarketresearch.com/cell-culture-market>

Next generation sequencing market - <https://www.alliedmarketresearch.com/next-generation-sequencing-market>

Anti-counterfeit packaging market - <https://www.alliedmarketresearch.com/anti-counterfeit-market>

Mass spectrometry market - <https://www.alliedmarketresearch.com/mass-spectrometry-market>

Immunohistochemistry market - <https://www.alliedmarketresearch.com/immunohistochemistry-market-A11199>

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Market Research

+ +1 800-792-5285

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/830115539>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.